Pharmaceutical Industry Reports Myeloproliferative Neoplasms Treatment Market | Page 2

REPORT DESCRIPTION
Myeloproliferative Neoplasms Treatment Market – Overview
Myeloproliferative Neoplasms (MPNs) are a group of rare disease, in which the bone marrow produces excess
blood cells. It can be white blood cells, red blood cells or platelets. The overproduction of blood cells by the bone
marrow creates hindrance in the smooth flow of blood, which leads to various symptoms such as progressive
cytopenias, cachexia and weight loss, splenomegaly, and blastic transformation. These conditions are developed
gradually over a period of time. Most people are diagnosed after the age of 60 years, when they were accompanied
by many other health issues, makes the treatment more difficult. The major symptoms associated with MPNs
include bleeding problem, anemia, chest pain, fatigue, enlarged spleen, and weight loss. According to Annals of
Hematology, approximately 90% of patients has experienced MPN-symptoms in past 12 months, wherein women
are reported to have higher overall burden than men. The treatment for myeloproliferative neoplasms is mainly
aimed to reduce the excess number of blood cells circulation. The concept of myleoproliferative disease was first
given by hematologist Williom Dameshek in 1950. However, in 2008, World Health Organization (WHO)
classified hematologic malignancies and renamed myloproliferative diseases to myeloproliferative neoplasms.
Rising awareness of molecular abnormalities and cellular pathways involved in the pathogenesis of MPNs is
expected to facilitate the development of novel drugs, propels the Myeloproliferative Neoplasms treatment market
growth in the near future
© Coherent market Insights. All Rights Reserved